Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 338-345

  Kwon, Janice S ^a   Mcalpine, Jessica N ^a   Hanley, Gillian E ^a   Finlayson, Sarah J ^a   Cohen, Trevor ^a   Miller, Dianne M ^a   Gilks, C Blake ^a   Huntsman, David G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ESTROGEN THERAPY; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; HYSTERECTOMY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICAL FEE; MONTE CARLO METHOD; OPPORTUNISTIC SALPINGECTOMY; OVARIECTOMY; OVARY CANCER; OVARY FUNCTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; SURGICAL RISK; UTERINE TUBE LIGATION; VAGINAL HYSTERECTOMY; COMPARATIVE STUDY; COMPUTER SIMULATION; ECONOMICS; MIDDLE AGED; OVARIAN NEOPLASMS; STATISTICAL MODEL;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; OVARIAN NEOPLASMS; SALPINGECTOMY;

EID: 84922447911     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000630     Document Type: Article

References (50)

1. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009; 19: 58-64
2. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-16
3. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9
4. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-6
5. OVCARE. Preventing ovarian cancer 2010. 2014. Available at: http://www.ovcare.ca/prevention. Retrieved January 23, 2014
6. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-Term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013; 121: 709-16
7. Narod SA. Salpingectomy to prevent ovarian cancer: A Countercurrents Series. Curr Oncol 2013; 20: 145-7
8. Herzog TJ, Dinkelspiel HE. Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? Curr Oncol 2013; 20: 148-51
9. Medical Services Commission. Medical services commission payment schedule: obstetrics and gynecology 2014. 2014. Available at: http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/pdf/26-obstetrics-gynecology.pdf. Retrieved June 30, 2014
10. Canadian Institute for Health Information. Patient cost estimator 2014. 2014. Available at: http://www.cihi.ca/CIHI-ext-portal/internet/en/documentfull/spending+and+health+workforce/spending/pce-application. Retrieved January 23, 2014
11. de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open 2013; 1: E1-8
12. Statistics Canada. Average earnings by sex and work pattern: Statistics Canada, Government of Canada. 2014. Available at: http://www.statcan.gc.ca/tables-Tableaux/sum-som/l01/cst01/labor01a-eng.htm. Retrieved January 23, 2014
13. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-Adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25: 667-77
14. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8
15. Statistics Canada. Complete life table, Canada, 2000 to 2002: females 2006. 2014. Available at: http://www.statcan.gc.ca/pub/84-537-x/t/pdf/4198611-eng.pdf. Retrieved January 23, 2014
16. Canadian Cancer Society. Canadian cancer statistics 2014. Toronto (Canada): Canadian Cancer Society; 2014. Available at: http://www.cancer.ca/;/media/cancer.ca/CW/cancer information/cancer 101/Canadian cancer statistics/Canadian-Cancer-Statistics-2014-EN.pdf. Retrieved June 30, 2014
17. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120: 470-3
18. OVCARE. About ovarian cancer: can we prevent it? 2010. Available at: http://www.ovcare.ca/about-ovarian-cancer/. Retrieved July 25, 2014
19. Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 2014; 102: 192-198.e3
20. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-Analysis. J Ovarian Res 2012; 5: 13
21. Read MD, Edey KA, Hapeshi J, Foy C. Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study. Menopause Int 2010; 16: 60-4
22. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013; 129: 448-51
23. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210: 471.e1-e11
24. Berlit S, Tuschy B, Kehl S, Brade J, Sutterlin M, Hornemann A. Laparoscopic supracervical hysterectomy with concomitant bilateral salpingectomy-why not? Anticancer Res 2013; 33: 2771-4
25. Vorwergk J, Radosa MP, Nicolaus K, Baus N, Jimenez Cruz J, Rengsberger M, et al. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 2014; 140: 859-65
26. Brummer TH, Jalkanen J, Fraser J, Heikkinen AM, Kauko M, Mäkinen J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. Hum Reprod 2011; 26: 1741-51
27. Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, et al. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. Int J Cancer 2013; 133: 2415-21
28. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013; 42: 579-89
29. Brisson M, Van de Velde N, De Wals P, Boily MC. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007; 177: 464-8
30. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004; 103: 619-31
31. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis 2013; 17: 193-202
32. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002; 94: 193-204
33. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-40
34. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113: 775-82
35. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-Analysis. Obstet Gynecol 2013; 122: 139-47
36. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-Analysis. Eur J Cancer 2010; 46: 2275-84
37. Camanni M, Mistrangelo E, Febo G, Ferrero B, Deltetto F. Prophylactic bilateral oophorectomy during vaginal hysterectomy for benign pathology. Arch Gynecol Obstet 2009; 280: 87-90
38. Cho HY, Kang SW, Kim HB, Park SH, Park ST. Prophylactic adnexectomy along with vaginal hysterectomy for benign pathology. Arch Gynecol Obstet 2012; 286: 1221-5
39. Paparella P, Sizzi O, Rossetti A, De Benedittis F, Paparella R. Vaginal hysterectomy in generally considered contraindications to vaginal surgery. Arch Gynecol Obstet 2004; 270: 104-9
40. Sheth SS. Adnexectomy for benign pathology at vaginal hysterectomy without laparoscopic assistance. BJOG 2002; 109: 1401-5
41. Paterson JM, Hux JE, Tu JV, Laupacis A. The Ontario Wait Time Strategy: No evidence of an adverse impact on other surgeries. ICES Investigative Report. Toronto (Canada): Institute for Clinical Evaluative Sciences; 2007
42. Fraser IS. Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception 2013; 87: 273-9
43. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of ectopic pregnancy after tubal sterilization. US Collaborative Review of Sterilization Working Group. N Engl J Med 1997; 336: 762-7
44. SEER. SEER stat fact sheets: ovary cancer. Available at: http://seer.cancer.gov/statfacts/html/ovary.html. Retrieved July 22, 2014
45. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy for benign gynecological disorders. Menopause 2007; 14: 580-5
46. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 2012; 109: 3921-6
47. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-Analysis. Hum Reprod Update 2011; 17: 55-67
48. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821-8
49. Medical Services Commission. Obstetrics and gynecology. Available at: http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/pdf/26-obstetrics-gynecology.pdf. Retrieved July 22, 2014
50. Healthcare bluebook. Available at: https://http://www.healthcarebluebook. com/. Retrieved October 14, 2014